|Criteria of acquired resistance to EGFR-TKIs in lung cancer by Jackman et al27|
|Clinical subtyping of acquired resistance to EGFR-directed TKI therapy in patients with NSCLC according to PD by Gandara et al28|
|Type of PD||Management|
|(1) CNS sanctuary PD||Local therapy (eg, surgery, radiotherapy or both) with continuation of the present EGFR-TKI|
|(2) Oligo-PD||Local therapy (eg, surgery, radiotherapy or both) with continuation of the present EGFR-TKI|
|(3) Systemic PD||If slowly progressing lesions, or lesions smaller than pretreatment, or progression without worsening of systemic symptoms and/or signs, continuation of the present EGFR-TKI may be considered|
CNS, central nervous system; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PD, progression disease; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor.